Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Shares Outstanding (Diluted Average) (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Shares Outstanding (Diluted Average) over the past 3 years, most recently at $8.5 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $8.5 million for Q4 2025, up 1055.9% from a year ago — trailing twelve months through Dec 2025 was $8.5 million (up 1055.9% YoY), and the annual figure for FY2025 was $8.5 million, up 1055.9%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $8.5 million at Tonix Pharmaceuticals Holding, up from $7.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for TNXP hit a ceiling of $10.3 million in Q1 2023 and a floor of $7925.0 in Q4 2023.
  • Median Shares Outstanding (Diluted Average) over the past 3 years was $730264.5 (2023), compared with a mean of $3.5 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 99.73% in 2024 and later soared 21155.22% in 2025.
  • Tonix Pharmaceuticals Holding's Shares Outstanding (Diluted Average) stood at $7925.0 in 2023, then surged by 9191.34% to $736339.0 in 2024, then soared by 1055.9% to $8.5 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $8.5 million (Q4 2025), $7.4 million (Q3 2025), and $6.6 million (Q2 2025) per Business Quant data.